How to Buy Adaptive Biotechnologies Stock
Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.
Adaptive Biotechnologies stock last closed at $12.56, up 1.21% from the previous day, and has increased 161.12% in one year. It has overperformed other stocks in the Biotechnology industry by 2.27 percentage points. Adaptive Biotechnologies stock is currently +215.5% from its 52-week low of $3.98, and -6.06% from its 52-week high of $13.37.
At the moment, there are 152.27M ADPT shares outstanding. The market cap of ADPT is $1.91B. In the last 24 hours, 2.2M ADPT shares were traded.
How to Buy Adaptive Biotechnologies Stock
Not sure how to invest in Adaptive Biotechnologies stock? Here's how.
- Choose where to buy Adaptive Biotechnologies stock: You need to pick a stock brokerage, but don't worry - we've sifted through dozens of online stock brokerages and apps to help you determine where to buy Adaptive Biotechnologies stock.
- Create your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Fund your investment account: Choose your payment method and add your information.
- Research Adaptive Biotechnologies stock: The Adaptive Biotechnologies ticker symbol is ADPT. Is Adaptive Biotechnologies stock a good investment? Should you buy shares of ADPT? How do ADPT's underlying business fundamentals look? Do top analysts think Adaptive Biotechnologies is a good buy? Why has ADPT's stock price moved recently? (Hint: Our stock research website can help you figure out if ADPT is a good stock to buy).
- Place your ADPT purchase: Decide if you will purchase ADPT shares at the current market price or use a limit order to buy ADPT shares at a particular price.
- Keep tabs on your ADPT investment: Create a watchlist to get live updates on your position in Adaptive Biotechnologies shares.
Step 1: Choose where to buy Adaptive Biotechnologies stock
You need an online brokerage account to access the NASDAQ market and buy ADPT shares.
Our recommended brokerage: eToro
Based on our analysis, eToro is the best place to buy stocks. Here's why:
- You can invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to world markets: From Tech to Utilities, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top stock exchanges.
- Social investing: eToro has a community of more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your share purchase by creating an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've selected the best brokerage, you need to fill out some personal details so you are able to buy ADPT today.
How to Open a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal details to open your new brokerage account.
- Send your data by pressing the "Create Account" button. Get started with eToro today
Step 3: Fund your investment account
Now that you have finished signing up on apps for stocks, your next step is to transfer the money for your investment:
Check out the tutorial below if you need help depositing funds into your brokerage account.
Step 4: Research Adaptive Biotechnologies stock
Once you have figured out the best place to buy Adaptive Biotechnologies stock, it's very important to analyze their stock prior to buying, so you truly understand the risk and opportunity.
Adaptive Biotechnologies Numbers
Adaptive Biotechnologies Due Diligence Checks
WallStreetZen was built to help everyday investors do more in-depth fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on ADPT's stock page.
Is ADPT stock overvalued?
Investors use a variety of different financial metrics, analyses, models, and charts to gauge ADPT's intrinsic value.
Using relative valuations metrics:
- ADPT may be overvalued based on its P/B ratio of 10.64x, relative to Biotechnology industry P/B ratio of 4.49x
You can access additional valuation research on ADPT's stock here.
How do ADPT Financials look?
Pros:
- There are more short-term assets than short-term liabilities on the ADPT balance sheet.
- ADPT has $200.59M in cash and short term investments. This is sufficient to cover its annual cash burn of $82.81M.
- ADPT has cash burn of 82808000. It has sufficient cash and short-term investments to cover this for at least one year.
- There are more short-term assets than long-term liabilities on the ADPT balance sheet.
Cons:
- ADPT has a relatively high debt to equity ratio of 1.76.
- Total ADPT debt is higher than 5 years ago, relative to shareholder equity.
- ADPT profit margin has gone up by 0.67 percentage points in the past year, but the company is still unprofitable.
Is it a good time to buy ADPT stock, according to analysts?
Out of 6 Wall Street analysts who monitor ADPT, the consensus analyst rating on ADPT is a Strong Buy
Please keep in mind that analyst forecasts are not recommendations, nor are they financial advice.
Latest ADPT Analyst Forecasts
Salveen Richter, a top 39% analyst from Goldman Sachs maintains ADPT with a strong buy rating and raises their ADPT price target from $9.00 to $10.00, on May 2, 2025.
You can dig deeper into what analysts are saying on the Adaptive Biotechnologies stock forecast page.
ADPT Technicals
How are ADPT Revenues/Earnings doing?
Last year, ADPT revenue was $205.22M. In the last 5 year, ADPT's revenue has gone up by 17.36% per year. This was slower than the Biotechnology industry average of 63.89%.
You can research ADPT's earnings and revenue performance here.
Who is buying/selling ADPT?
In the last year, insiders at ADPT have sold more shares than they have bought.
Kyle Piskel, Chief Financial Officer of ADPT, was the latest ADPT insider to sell. They sold $17,148.81 worth of ADPT shares on May 16, 2025.
Research more about who owns ADPT stock here.
Can I get consistent income from ADPT stock?
No, Adaptive Biotechnologies doesn't provide an income stream by paying out dividends.
What others are saying about ADPT
One of the major reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other traders have to say.
Step 5: Place your ADPT purchase
There are two primary options:
- Market order: A market order is an order to buy or sell a security at the best possible price.
Market orders are generally fine. - Limit order: A limit order allows you to buy or sell a security at a specific price (or better).
If you want to be certain you're buying or selling at a particular dollar amount, use a limit order.
Click the Open button and eToro will execute your order.
If you want more help with investing in stocks on eToro, click the helpful video below:
Step 6: Keep tabs on your ADPT investment
Now that you own some ADPT shares, you'll want to keep up with your new investment.
Start a watchlist to track the latest developments regarding your ADPT stock.
ADPT Feed
How to Buy Stock in Adaptive Biotechnologies
To reiterate, here are the 6 steps for buying Adaptive Biotechnologies stock:
- Choose where to buy Adaptive Biotechnologies stock
- Create your brokerage account
- Fund your investment account
- Research Adaptive Biotechnologies stock
- Place your ADPT purchase
- Keep tabs on your ADPT investment
If you need a place to buy stocks, eToro is our favorite option.
Get Started with eToro TodayIf you would like to keep tabs on your investment in Adaptive Biotechnologies, hit the button below to create your watchlist.
Trending "How To" Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.